1. Expert Insights Into What's Hot in Glaucoma

2. This program will include a discussion of investigational agents and devices not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Glaucoma Can Result in Blindness

4. Poor Compliance Can Increase Risk of Progression

5. Problems With Drops vs Risks of Traditional Surgery

6. Minimally Invasive Surgery Fills Treatment Gap

7. Minimally Invasive Glaucoma Surgery (MIGS)

8. Adverse Effects of Traditional Surgical Approaches

9. MIGS Classified by Mechanism of Action: Trabecular Meshwork

10. MIGS Classified by Mechanism of Action: Schlemm Canal

11. MIGS Classified by Mechanism of Action: Suprachoroidal Space

12. MIGS Classified by Mechanism of Action: Subconjunctival Space

13. MIGS Used in Combined Procedures

14. MIGS Standalone or With Cataract Surgery

15. MIGS Benefits Ophthalmologists and Patients

16. Controlled Glaucoma Redefined

17. Complicated Patient Case

18. Solution for the Complicated Case

19. MIGS Allows General Ophthalmologists to Do Glaucoma Surgery

20. Remembering Basic Ocular Anatomy

21. Choosing Procedures

22. Matching Patients and Procedures

23. Multiple Devices Allow Individualized Care

24. More New Technologies: Hydrus Microstent

25. More New Technologies: iStent Inject

26. Safety of MIGS Procedures

27. Why General Ophthalmologists Should Consider Adding MIGS to Their Practices

28. Poor Candidates for MIGS

29. Steps for Incorporating MIGS Into Practice

30. Tips for Gonioscopy

31. New Medications: Latanoprostene Bunod

32. Rho Kinase Inhibitors

33. Netarsudil/Latanoprost Combination

34. New Drug Delivery Devices

35. New Techniques, New Medications, New Devices Mean New Era in Treatment

36. Incorporate New Options Into Practice

37. Abbreviations